PLX Stock Risk & Deep Value Analysis
Protalix Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PLX Stock
We analyzed Protalix Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PLX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PLX Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Upcoming Risk Events
- 📅
Unfavorable clinical trial results for PRX-115 or other pipeline candidates
- 📅
Slower-than-expected uptake of Elfabrio's E4W dosing regimen
- 📅
Increased competition in the Fabry disease market or target rare renal indications
- 📅
Future equity dilution via active S-3 shelf filing without proportional revenue growth
Unlock PLX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Protalix Biotherapeutics Inc (PLX) Do?
Market Cap
$172.42M
Sector
Healthcare
Industry
Biotechnology
Employees
213
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Visit Protalix Biotherapeutics Inc WebsiteInvestment Thesis
Protalix is an undervalued rare disease biotech with a proprietary platform and a cornerstone commercial product (Elfabrio) gaining significant market traction through a strategic partnership. The recent EC approval for enhanced dosing, combined with a substantial milestone payment and strong 2026 revenue guidance, significantly de-risks the financial profile and provides a clear runway for pipeline development. The potential for new assets in rare renal diseases and gout, coupled with institutional interest, positions PLX for substantial re-rating and 10x growth as it moves towards sustained profitability and broader market acceptance of its plant-based therapeutic approach.
Is PLX Stock Undervalued?
Unlock the full AI analysis for PLX
Get the complete DVR score, risk analysis, and more
PLX Price Targets & Strategy
12-Month Target
$11.00
Bull Case
$15.75
Bear Case
$1.50
Valuation Basis
Based on 8x P/S multiple applied to mid-range 2026 revenue guidance of $80M, reflecting Elfabrio's expanded market, pipeline potential, and improved financial stability ($640M market cap / 61.8M shares outstanding = ~$10.35, rounding to $11.00 for analyst median alignment).
Entry Strategy
Consider dollar-cost averaging in the range of $1.80-$2.20, near recent support levels, particularly after any market overreaction to broader biotech volatility. Optimal entry would be below $2.00.
Exit Strategy
Take initial profits at $7.00-$8.00, securing further gains at $11.00-$12.00. Implement a stop-loss at $1.50, reflecting fundamental deterioration if key catalysts fail.
Portfolio Allocation
5% for aggressive risk tolerance, considering the inherent volatility and growth potential of small-cap biotech.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PLX Financially Healthy?
Valuation
P/E Ratio
31.70
Forward P/E
30.57
PEG Ratio
1.40
Price/Book
2.70
Price/Sales
2.10
Profitability
Net Margin
-12.50%
Return on Equity
6.79%
Revenue Growth
30.50%
EPS
$-0.08
Balance Sheet
Cash & Equivalents
$30.30M
Other
Dividend Yield
2.42%
Does PLX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat, primarily derived from its proprietary ProCellEx platform and patented drug formulations like Elfabrio, is strengthening with successful regulatory approvals and the development of new pipeline candidates. The E4W dosing approval enhances patient adherence and market stickiness, making it harder for competitors to displace. However, the durability is reliant on continued clinical success and commercial execution.
Moat Erosion Risks
- •Loss of patent protection or emergence of biosimilars/next-gen therapies
- •Failure of pipeline candidates to achieve regulatory approval or market acceptance
- •Intense competition from larger pharmaceutical companies with greater R&D and commercial resources
PLX Competitive Moat Analysis
Sign up to see competitive advantages
PLX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by recent positive news and analyst upgrades, but limited widespread retail discussion.
Institutional Sentiment
Positive, evidenced by HC Wainwright's upgrade of FY2026 EPS forecast to $0.26 and maintaining a Buy rating with a $12.00 price target. Goldman Sachs Group increased its stake by 482.3% in Q1 2026.
Insider Activity (Form 4)
Goldman Sachs Group increased its stake by 482.3% in Q1 2026. No specific Form 4 filings (names, titles, share quantities, dollar values) were provided in the research for the last 90 days for company insiders.
Options Flow
Normal options activity, with no specific unusual put/call ratio or large block trades identified in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026 results)
Surprise Probability
Medium, given the recent miss on Q4 2025 EPS despite positive strategic developments. Q1 will be key to validate 2026 guidance.
Historical Earnings Pattern
Historically, stock performance has been highly sensitive to clinical milestones, regulatory approvals, and cash runway updates, often showing significant volatility around these announcements.
Key Metrics to Watch
Competitive Position
Top Competitor
SANOFI (SNY) or TAKEDA PHARMACEUTICAL (TAK) for broader rare disease portfolios, or AMICUS THERAPEUTICS (FOLD) for Fabry disease specific. (Specific detailed competitor data not provided in research brief.)
Market Share Trend
Gaining ground with Elfabrio's enhanced competitive profile (E4W dosing approval), potentially increasing its share in the Fabry disease market.
Valuation vs Peers
Trading at a P/S of 3.3-3.4x on TTM revenue. This is at the lower end for innovative rare disease biotechs, suggesting potential for multiple expansion if 2026 guidance is achieved and sustained. Forward P/E is difficult to compare due to early profitability stage and varying analyst estimates.
Competitive Advantages
- •Proprietary ProCellEx plant cell expression platform
- •Strategic partnerships with established pharmaceutical companies (Chiesi for Elfabrio, Pfizer for Elelyso)
- •EC approval of Elfabrio's E4W dosing improving patient convenience and market appeal
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PLX Stock Higher?
Near-Term (0-6 months)
- •Receipt of $25.0 million milestone payment from Chiesi (Expected Q1 2026)
- •Q1 2026 Earnings Report (Estimated early-May 2026), with updates on Elfabrio uptake and cash position
- •Further expansion of Elfabrio's market penetration across Europe due to E4W dosing
Medium-Term (6-18 months)
- •Phase 2 clinical data readout for PRX-115 (uncontrolled gout)
- •Progress on strategic focus for rare renal diseases (PRX-119 and Secarna collaboration)
- •Potential additional milestone payments from Chiesi based on Elfabrio sales performance
Long-Term (18+ months)
- •Launch of new proprietary pipeline assets (PRX-115, PRX-119) with retained commercial rights
- •Establishment of Protalix as a leader in plant-based rare disease therapeutics
- •Strategic shift towards internal commercialization or higher-value partnerships
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PLX?
- ✓
Acceleration in Elfabrio's reported sales/royalties by Chiesi
- ✓
Positive clinical data for PRX-115 or PRX-119
- ✓
Successful commercialization of new pipeline assets that retain higher ownership stakes for PLX
- ✓
Consistent reduction in operational cash burn towards free cash flow positivity
Bull Case Analysis
See what could go right with Premium
Competing with PLX
See how Protalix Biotherapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Protalix Biotherapeutics Inc PLX | $172.4M | 7.6 | 31.7 | $52.7M | -12.5% | 30.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Protalix Biotherapeutics Inc (PLX)?
As of March 24, 2026, Protalix Biotherapeutics Inc has a DVR Score of 7.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Protalix Biotherapeutics Inc?
Protalix Biotherapeutics Inc's market capitalization is approximately $172.4M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Protalix Biotherapeutics Inc use?
PLX is the ticker symbol for Protalix Biotherapeutics Inc. The company trades on the ASE.
What is the risk level for PLX stock?
Our analysis rates Protalix Biotherapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PLX?
Protalix Biotherapeutics Inc currently has a price-to-earnings (P/E) ratio of 31.7. This is above the market average, suggesting the stock may be priced for high growth expectations.
Does Protalix Biotherapeutics Inc pay a dividend?
Yes, Protalix Biotherapeutics Inc pays a dividend with a current yield of approximately 2.42%.
Is Protalix Biotherapeutics Inc's revenue growing?
Protalix Biotherapeutics Inc has reported revenue growth of 30.5%. The company is showing strong top-line momentum.
Is PLX stock profitable?
Protalix Biotherapeutics Inc has a profit margin of -12.5%. The company is currently unprofitable.
How often is the PLX DVR analysis updated?
Our AI-powered analysis of Protalix Biotherapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PLX (Protalix Biotherapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.